연구동향 분석

Dose KRAS Mutation Status Affect on the Effect of VEGF Therapy in Metastatic Colon Cancer Patients?

김승태 박경화 신상원 김열홍 2014년

논문상세정보
인용/피인용
' Dose KRAS Mutation Status Affect on the Effect of VEGF Therapy in Metastatic Colon Cancer Patients?' 의 주제별 논문영향력
논문영향력 선정 방법
논문영향력 요약
주제
  • 내과학
  • colonic neoplasms
  • kras
  • vascular endothelial growth factor
동일주제 총논문수 논문피인용 총횟수 주제별 논문영향력의 평균
1,375 0

0.0%

' Dose KRAS Mutation Status Affect on the Effect of VEGF Therapy in Metastatic Colon Cancer Patients?' 의 참고문헌

  • Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer
    Amado RG J Clin Oncol 26 : 1626 ~ 1634 [2008]
  • Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer
    Amado RG J Clin Oncol 26 1626-1634 [2008]
  • Ras modulates Myc activity to repress thrombospondin-1 expression and increase tumor angiogenesis
    Watnick RS Cancer Cell 3 : 219 ~ 231 [2003]
  • Ras modulates Myc activity to repress thrombospondin-1 expression and increase tumor angiogenesis
    Watnick RS Cancer Cell 3 219-231 [2003]
  • Oxaliplatin-based chemotherapy in the management of colorectal cancer
    Capdevila J Expert Rev Anticancer Ther 8 : 1223 ~ 1236 [2008]
  • Oxaliplatin-based chemotherapy in the management of colorectal cancer
    Capdevila J Expert Rev Anticancer Ther 8 1223-1236 [2008]
  • Oncogenes and tumor angiogenesis: differential modes of vascular endothelial growth factor up-regulation in ras-transformed epithelial cells and fibroblasts
    Rak J Cancer Res 60 : 490 ~ 498 [2000]
  • Oncogenes and tumor angiogenesis: differential modes of vascular endothelial growth factor up-regulation in ras-transformed epithelial cells and fibroblasts
    Rak J Cancer Res 60 490-498 [2000]
  • Mutations of APC, K-ras, and p53 are associated with specific chromosomal aberrations in colorectal adenocarcinomas
    Leslie A Cancer Res 63 : 4656 ~ 4661 [2003]
  • Mutations of APC, K-ras, and p53 are associated with specific chromosomal aberrations in colorectal adenocarcinomas
    Leslie A Cancer Res 63 4656-4661 [2003]
  • Mutant ras oncogenes upregulate VEGF/VPF expression : implications for induction and inhibition of tumor angiogenesis
    Rak J Cancer Res 55 : 4575 ~ 4580 [1995]
  • Mutant ras oncogenes upregulate VEGF/VPF expression : implications for induction and inhibition of tumor angiogenesis
    Rak J Cancer Res 55 4575-4580 [1995]
  • Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study
    Andreyev HJ Br J Cancer 85 692-696 [2001]
  • Kirsten ras mutations in patients with colorectal cancer : the 'RASCAL II' study
    Andreyev HJ Br J Cancer 85 : 692 ~ 696 [2001]
  • K-ras mutations and benefit from cetuximab in advanced colorectal cancer
    Karapetis CS N Engl J Med 359 : 1757 ~ 1765 [2008]
  • K-ras mutations and benefit from cetuximab in advanced colorectal cancer
    Karapetis CS N Engl J Med 359 1757-1765 [2008]
  • Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo
    Kim KJ Nature 362 : 841 ~ 844 [1993]
  • Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo
    Kim KJ Nature 362 841-844 [1993]
  • Impact of KRAS and BRAF gene mutation status on outcomes from the Phase III AGITG MAX Trial of capecitabine alone or in Combination with bevacizumab and mitomycin in advanced colorectal cancer
    Price TJ J Clin Oncol 29 : 2675 ~ 2682 [2011]
  • Impact of KRAS and BRAF gene mutation status on outcomes from the Phase III AGITG MAX Trial of capecitabine alone or in Combination with bevacizumab and mitomycin in advanced colorectal cancer
    Price TJ J Clin Oncol 29 2675-2682 [2011]
  • Global cancer statistics
    Jemal A CA Cancer J Clin 61 : 69 ~ 90 [2011]
  • Global cancer statistics
    Jemal A CA Cancer J Clin 61 69-90 [2011]
  • Expression of vascular endothelial growth factor, hypoxia inducible factor 1alpha, and carbonic anhydrase IX in human tumours
    Jubb AM J Clin Pathol 57 : 504 ~ 512 [2004]
  • Expression of vascular endothelial growth factor, hypoxia inducible factor 1alpha, and carbonic anhydrase IX in human tumours
    Jubb AM J Clin Pathol 57 504-512 [2004]
  • Essential role for oncogenic Ras in tumour maintenance
    Chin L Nature 400 : 468 ~ 472 [1999]
  • Essential role for oncogenic Ras in tumour maintenance
    Chin L Nature 400 468-472 [1999]
  • Epidermal growth factor receptor in tumor angiogenesis
    Ellis LM Hematol Oncol Clin North Am 18 : 1007 ~ 1021 [2004]
  • Epidermal growth factor receptor in tumor angiogenesis
    Ellis LM Hematol Oncol Clin North Am 18 1007-1021 [2004]
  • Effect of KRAS codon13 mutations in patients with advanced colorectal cancer(advanced CRC)under oxaliplatin containing chemotherapy : results from a translational study of the AIO colorectal study group
    Reinacher-Schick A BMC Cancer 12 : 349 ~ [2012]
  • Effect of KRAS codon13 mutations in patients with advanced colorectal cancer(advanced CRC)under oxaliplatin containing chemotherapy : results from a translational study of the AIO colorectal study group
    Reinacher-Schick A BMC Cancer 12 349- [2012]
  • Costs and cost effectiveness of a health care provider-directed intervention to promote colorectal cancer screening
    Shankaran V J Clin Oncol 27 : 5370 ~ 5375 [2009]
  • Costs and cost effectiveness of a health care provider-directed intervention to promote colorectal cancer screening
    Shankaran V J Clin Oncol 27 5370-5375 [2009]
  • Complete inhibition of angiogenesis and growth of microtumors by anti-vascular endothelial growth factor neutralizing antibody : novel concepts of angiostatic therapy from intravital videomicroscopy
    Borgstrom P Cancer Res 56 : 4032 ~ 4039 [1996]
  • Complete inhibition of angiogenesis and growth of microtumors by anti-vascular endothelial growth factor neutralizing antibody : novel concepts of angiostatic therapy from intravital videomicroscopy
    Borgstrom P Cancer Res 56 4032-4039 [1996]
  • Cetuximab : a review of its use in squamous cell carcinoma of the head and neck and metastatic colorectal cancer
    Blick SK Drugs 67 : 2585 ~ 2607 [2007]
  • Cetuximab : a review of its use in squamous cell carcinoma of the head and neck and metastatic colorectal cancer
    Blick SK Drugs 67 2585-2607 [2007]
  • Capecitabine, alone and in combination, in the management of patients with colorectal cancer: a review of the evidence
    Comella P Drugs 68 : 949 ~ 961 [2008]
  • Capecitabine, alone and in combination, in the management of patients with colorectal cancer: a review of the evidence
    Comella P Drugs 68 949-961 [2008]
  • Blockade of epidermal growth factor receptor signaling in tumor cells and tumor-associated endothelial cells for therapy of androgen-independent human prostate cancer growing in the bone of nude mice
    Kim SJ Clin Cancer Res 9 : 1200 ~ 1210 [2003]
  • Blockade of epidermal growth factor receptor signaling in tumor cells and tumor-associated endothelial cells for therapy of androgen-independent human prostate cancer growing in the bone of nude mice
    Kim SJ Clin Cancer Res 9 1200-1210 [2003]
  • Biomarkers to predict the clinical efficacy of bevacizumab in cancer
    Jubb AM Lancet Oncol 11 : 1172 ~ 1183 [2010]
  • Biomarkers to predict the clinical efficacy of bevacizumab in cancer
    Jubb AM Lancet Oncol 11 1172-1183 [2010]
  • Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
    Hurwitz H N Engl J Med 350 : 2335 ~ 2342 [2004]
  • Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
    Hurwitz H N Engl J Med 350 2335-2342 [2004]
  • Bevacizumab : a review of its use in metastatic colorectal cancer
    McCormack PL Drugs 68 : 487 ~ 506 [2008]
  • Bevacizumab : a review of its use in metastatic colorectal cancer
    McCormack PL Drugs 68 487-506 [2008]
  • A review of GERCOD trials of bimonthly leucovorin plus 5-fluorouracil 48-h continuous infusion in advanced colorectal cancer: evolution of a regimen
    de Gramont A Eur J Cancer 34 : 619 ~ 626 [1998]
  • A review of GERCOD trials of bimonthly leucovorin plus 5-fluorouracil 48-h continuous infusion in advanced colorectal cancer: evolution of a regimen
    de Gramont A Eur J Cancer 34 619-626 [1998]
  • A genetic model for colorectal tumorigenesis
    Fearon ER Cell 61 : 759 ~ 767 [1990]
  • A genetic model for colorectal tumorigenesis
    Fearon ER Cell 61 759-767 [1990]